The drug was developed through a global strategic collaboration between Kura Oncology and Kyowa Kirin Co., Ltd. (TSE:4151). Under the partnership, Kura leads development, regulatory, and commercial ...

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug ...

AML is a devastating blood cancer with low survival rates, particularly for older patients who cannot tolerate aggressive chemotherapy. Flashpoint's approach offers the potential for a new precision ...

Menin inhibitors have emerged as a clinically validated therapeutic class for the treatment of acute AML. However, first-generation inhibitors are limited by the rapid emergence of resistance ...

To help with this transition, DCI has named long-time partner RiskScout as its preferred BSA/AML and Fraud vendor to bring advanced financial crime solutions to users. RiskScout, a financial ...

Updated clinical development strategy based on positive data In the third quarter of 2025, Mendus shaped up its clinical development plans for the lead program vididencel in myeloid malignancies.The u ...

Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking ...

The Czech National Bank (CNB) has purchased Bitcoin and other digital assets worth $1 million, calling it a “test portfolio,” ...

Kura Oncology will host a conference call on November 13, 2025, at 12:30 pm ET / 9:30 am PT -SAN DIEGO and TOYKO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: ...

ShareVault, the modern platform built for high-stakes transactions, announced it has joined the Finalis Member Advantage Program, partnering with Finalis, a cloud-native platform-as-a-service (PaaS) ...

Taiwan’s Premier and Central Bank will study Bitcoin as a strategic reserve, draft pro-crypto rules, and pilot BTC treasury ...

The nation’s central bank has unveiled a pilot investment in Bitcoin, stablecoins, and tokenized deposits to better ...